{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:54:27Z","timestamp":1788872067337,"version":"build-2803163510"},"reference-count":107,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science KAKENHI","award":["23K19566"],"award-info":[{"award-number":["23K19566"]}]},{"name":"Japan Society for the Promotion of Science KAKENHI","award":["24K19148"],"award-info":[{"award-number":["24K19148"]}]},{"name":"Japan Society for the Promotion of Science KAKENHI","award":["2024048541"],"award-info":[{"award-number":["2024048541"]}]},{"name":"Takeda Science Foundation","award":["23K19566"],"award-info":[{"award-number":["23K19566"]}]},{"name":"Takeda Science Foundation","award":["24K19148"],"award-info":[{"award-number":["24K19148"]}]},{"name":"Takeda Science Foundation","award":["2024048541"],"award-info":[{"award-number":["2024048541"]}]},{"name":"Suzuken Memorial Foundation","award":["23K19566"],"award-info":[{"award-number":["23K19566"]}]},{"name":"Suzuken Memorial Foundation","award":["24K19148"],"award-info":[{"award-number":["24K19148"]}]},{"name":"Suzuken Memorial Foundation","award":["2024048541"],"award-info":[{"award-number":["2024048541"]}]},{"name":"Tsuchiya Foundation","award":["23K19566"],"award-info":[{"award-number":["23K19566"]}]},{"name":"Tsuchiya Foundation","award":["24K19148"],"award-info":[{"award-number":["24K19148"]}]},{"name":"Tsuchiya Foundation","award":["2024048541"],"award-info":[{"award-number":["2024048541"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Chronic kidney disease (CKD) is a major public health concern around the world. It is a significant risk factor for cardiovascular disease (CVD), and, as it progresses, the risk of cardiovascular events increases. Furthermore, end-stage kidney disease severely affects life expectancy and quality of life. Type 2 diabetes and hypertension are not only primary causes of CKD but also independent risk factors for CVD, which underscores the importance of effective treatment strategies for these conditions. The current therapies, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and sodium\u2013glucose co-transporter 2 inhibitors, are administered to control hypertension, slow the progression of CKD, and reduce cardiovascular risk. However, their efficacy remains suboptimal in certain instances. Mineralocorticoid receptor (MR), a nuclear receptor found in various tissues, such as the kidney and heart, plays a pivotal role in the progression of CKD. Overactivation of MR triggers inflammation and fibrosis, which exacerbates kidney damage and accelerates disease progression. MR antagonists (MRAs) have substantial beneficial effects in patients with cardiac and renal conditions; however, their use has been constrained because of adverse effects, such as hyperkalemia and kidney dysfunction. Recently, novel non-steroidal MRAs are more efficacious and have superior safety profiles to steroidal MRAs, making them promising potential components of future treatment strategies. Here, we discuss recent findings and the roles of MRAs in the management of hypertension and CKD, with a focus on the evidence obtained from fundamental research and major clinical trials.<\/jats:p>","DOI":"10.3390\/biomedicines13010053","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T14:21:12Z","timestamp":1735654872000},"page":"53","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Kisho","family":"Miyasako","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-2772","authenticated-orcid":false,"given":"Yujiro","family":"Maeoka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","article-title":"Vascular Type I Aldosterone Binding Sites Are Physiological Mineralocorticoid Receptors","volume":"125","author":"Funder","year":"1989","journal-title":"Endocrinology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of Human Mineralocorticoid Receptor Complementary DNA: Structural and Functional Kinship with the Glucocorticoid Receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.vh.2018.09.004","article-title":"Mechanisms of Mineralocorticoid Receptor Signaling","volume":"109","author":"Fuller","year":"2019","journal-title":"Vitam. Horm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1681\/ASN.2015070815","article-title":"Direct and Indirect Mineralocorticoid Effects Determine Distal Salt Transport","volume":"27","author":"Terker","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMra2030212","article-title":"Insights into Salt Handling and Blood Pressure","volume":"385","author":"Ellison","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Blocker (MRB) in Hypertension and Chronic Kidney Disease","volume":"35","author":"Wan","year":"2021","journal-title":"J. Hum. Hypertens."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","article-title":"Home Blood Pressure-Lowering Effect of a Non-Steroidal Mineralocorticoid Receptor Blocker, Esaxerenone, versus Trichlormethiazide for Uncontrolled Hypertension: The EXCITE-HT Randomized Controlled Study","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/ajh\/hpaa155","article-title":"Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study","volume":"34","author":"Kario","year":"2021","journal-title":"Am. J. Hypertens."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in Type 2 Diabetic Nephropathy: Effects on Proteinuria, Blood Pressure and Renal Function","volume":"24","author":"Baggen","year":"2006","journal-title":"J. Hypertens."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(09)61600-7","article-title":"Resistant hypertension: An Unmet Treatment Need","volume":"374","author":"Williams","year":"2009","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological Blood Pressure Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure: An Individual Participant-Level Data Meta-Analysis","volume":"397","author":"Pouchain","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10641963.2016.1246564","article-title":"Addition of Spironolactone in Patients with Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials","volume":"39","author":"Liu","year":"2017","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension (PATHWAY-2): A Randomised, Double-Blind, Crossover Trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cvr\/cvad165","article-title":"Efficacy of Pharmacological and Interventional Treatment for Resistant Hypertension: A Network Meta-Analysis","volume":"120","author":"Tian","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e018827","DOI":"10.1161\/JAHA.120.018827","article-title":"Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension","volume":"9","author":"Tsujimoto","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Krasinska, B., Cofta, S., Szczepaniak-Chichel, L., Rzymski, P., Trafas, T., Paluszkiewicz, L., Tykarski, A., and Krasinski, Z. (2019). The Effects of Eplerenone on the Circadian Blood Pressure Pattern and Left Ventricular Hypertrophy in Patients with Obstructive Sleep Apnea and Resistant Hypertension-A Randomized, Controlled Trial. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101671"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10554-023-03013-7","article-title":"Spironolactone Improves Left Atrial Function and Atrioventricular Coupling in Patients with Resistant Hypertension","volume":"40","author":"Girard","year":"2024","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e019434","DOI":"10.1161\/JAHA.120.019434","article-title":"Spironolactone Reduces Aortic Stiffness in Patients with Resistant Hypertension Independent of Blood Pressure Change","volume":"10","author":"Aryal","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/01.CIR.44.6.971","article-title":"Biochemical Profiling and the Natural History of Hypertensive Diseases: Low-Renin Essential Hypertension, a Benign Condition","volume":"44","author":"Laragh","year":"1971","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/ndt\/gft052","article-title":"Primary Aldosteronism and Low-Renin Hypertension: A Continuum?","volume":"28","author":"Funder","year":"2013","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"bvae113","DOI":"10.1210\/jendso\/bvae113","article-title":"Prevalence and Characteristics of Low-Renin Hypertension in a Primary Care Population","volume":"8","author":"Shah","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and Haemodynamic Changes in Resistant Hypertension, and Blood Pressure Responses to Spironolactone or Amiloride: The PATHWAY-2 Mechanisms Substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"F325","DOI":"10.1152\/ajprenal.00415.2020","article-title":"Aldosterone Sensitivity: An Opportunity to Explore the Pathogenesis of Hypertension","volume":"320","author":"Gray","year":"2021","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_31","first-page":"e484","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41371-023-00891-1","article-title":"Efficacy and Safety of Mineralocorticoid Receptor Antagonists for the Treatment of Low-Renin Hypertension: A Systematic Review and Meta-Analysis","volume":"38","author":"Shah","year":"2024","journal-title":"J. Hum. Hypertens."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ajh\/hpad032","article-title":"Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension","volume":"36","author":"Mansur","year":"2023","journal-title":"Am. J. Hypertens."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41371-024-00931-4","article-title":"A Randomized Trial Assessing Efficacy and Safety of Mineralocorticoid Receptor Antagonist Therapy Compared to Standard Antihypertensive Therapy in hypErtension with low Renin (REMASTER): Rationale and study design","volume":"38","author":"Shah","year":"2024","journal-title":"J. Hum. Hypertens."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","article-title":"Antihypertensive Effects and Safety of Esaxerenone in Patients with Moderate Kidney Dysfunction","volume":"44","author":"Ito","year":"2021","journal-title":"Hypertens. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/HJH.0b013e328332b79b","article-title":"Does the Ratio of Serum Aldosterone to Plasma Renin Activity Predict the Efficacy of Diuretics in Hypertension? Results of RENALDO","volume":"28","author":"Parthasarathy","year":"2010","journal-title":"J. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","article-title":"Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone","volume":"79","author":"Maeoka","year":"2022","journal-title":"Hypertension"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1681\/ASN.2017030345","article-title":"Plasma Potassium Determines NCC Abundance in Adult Kidney-Specific gammaENaC Knockout","volume":"29","author":"Boscardin","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00424-015-1785-2","article-title":"Adult Nephron-Specific MR-Deficient Mice Develop a Severe renal PHA-1 Phenotype","volume":"468","author":"Canonica","year":"2016","journal-title":"Pflug. Arch."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1681\/ASN.2006090975","article-title":"Impairment of Sodium Balance in Mice Deficient in Renal Principal Cell Mineralocorticoid Receptor","volume":"18","author":"Ronzaud","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"F1289","DOI":"10.1152\/ajprenal.00247.2012","article-title":"Aldosterone-Dependent and -Independent Regulation of the Epithelial Sodium Channel (ENaC) in Mouse Distal Nephron","volume":"303","author":"Nesterov","year":"2012","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e014996","DOI":"10.1161\/JAHA.119.014996","article-title":"Effect of Angiotensin II on ENaC in the Distal Convoluted Tubule and in the Cortical Collecting Duct of Mineralocorticoid Receptor Deficient Mice","volume":"9","author":"Wu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_44","unstructured":"GBD Chronic Kidney Disease Collaboration (2020). Global, Regional, and National Burden of Chronic Kidney Disease, 1990\u20132017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709\u2013733."},{"key":"ref_45","unstructured":"GBD Chronic Kidney Disease Collaboration (2023). Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet, 402, 203\u2013234."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide Trends in Hypertension Prevalence and Progress in Treatment and Control from 1990 to 2019: A Pooled Analysis of 1201 Population-Representative Studies with 104 Million Participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The Case for Early Identification and Intervention of Chronic Kidney Disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1681\/ASN.2018101037","article-title":"Burden of CKD and Cardiovascular Disease on Life Expectancy and Health Service Utilization: A Cohort Study of Hong Kong Chinese Hypertensive Patients","volume":"30","author":"Wan","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global Kidney Health 2017 and Beyond: A Roadmap for Closing Gaps in Care, Research, and Policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The Definition, Classification, and Prognosis of Chronic Kidney Disease: A KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"Khunti","year":"2022","journal-title":"Kidney Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/ndt\/gfac284","article-title":"Steroidal or Non-Steroidal MRAs: Should We Still Enable RAASi Use Through K binders?","volume":"38","author":"Gregg","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Yang, C.T., Kor, C.T., and Hsieh, Y.P. (2018). Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease. J. Clin. Med., 7.","DOI":"10.3390\/jcm7110459"},{"key":"ref_62","first-page":"CD007004","article-title":"Aldosterone Antagonists in Addition to Renin Angiotensin System Antagonists for Preventing the Progression of Chronic Kidney Disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jdi.13778","article-title":"Reduction in the Magnitude of Serum Potassium Elevation in Combination Therapy with Esaxerenone (CS-3150) and Sodium-Glucose Cotransporter 2 Inhibitor in Patients with Diabetic Kidney Disease: Subanalysis of Two Phase III Studies","volume":"13","author":"Shikata","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone and EmpaglifloziN in Participants with CHRONIC kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and Consequences of Renal Function Variations with Aldosterone Blocker Therapy in Heart Failure Patients after Myocardial Infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure: Insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.acvd.2020.03.018","article-title":"Practical Management of Worsening Renal Function in Outpatients with Heart Failure and Reduced Ejection Fraction: Statement from a Panel of Multidisciplinary Experts and the Heart Failure Working Group of the French Society of Cardiology","volume":"113","author":"Mewton","year":"2020","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of Guideline-Recommended MEDICAL therapy in Patients with Heart Failure and Chronic Kidney Disease: From Physician\u2019s Prescriptions to Patient\u2019s Dispensations, Medication Adherence and Persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of Kidney Function Throughout the Heart Failure Trajectory\u2014A Position Statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.ki.5002273","article-title":"Chronic Kidney Disease Management in the United Kingdom: NEOERICA Project Results","volume":"72","author":"Stevens","year":"2007","journal-title":"Kidney Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of Death in Patients with Reduced Kidney Function","volume":"26","author":"Thompson","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jchf.2022.06.010","article-title":"Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs","volume":"10","author":"Ferreira","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2015.01.014","article-title":"Clinical Benefit of Spironolactone in Patients with Acute Decompensated Heart Failure and Severe Renal Dysfunction: Data from the Korean Heart Failure Registry","volume":"169","author":"Oh","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2017.03.080","article-title":"Effect of Spironolactone on the Risks of Mortality and Hospitalization for Heart Failure in Pre-Dialysis Advanced Chronic kidney Disease: A Nationwide Population-Based Study","volume":"238","author":"Tseng","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amjcard.2014.03.062","article-title":"Spironolactone Use and Higher Hospital Readmission for Medicare Beneficiaries with Heart Failure, Left Ventricular Ejection Fraction <45%, and Estimated Glomerular Filtration Rate <45 ml\/min\/1.73 m2","volume":"114","author":"Inampudi","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the Target for Aldosterone: Roles of Oxidative Stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/Salt Induces Renal Inflammation and Fibrosis in Hypertensive Rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1042\/CS103S025S","article-title":"Contribution of Endothelin-1 to Renal Activator Protein-1 Activation and Macrophage Infiltration in Aldosterone-Induced Hypertension","volume":"103","author":"Tostes","year":"2002","journal-title":"Clin. Sci. Lond."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone Induces a Vascular Inflammatory Phenotype in the Rat Heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of Mineralocorticoid Receptor Function by Rac1 GTPase: Implication in Proteinuric Kidney Disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","article-title":"Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db\/db Mice","volume":"78","author":"Hirohama","year":"2021","journal-title":"Hypertension"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41440-022-01036-6","article-title":"Mechanisms of Mineralocorticoid Receptor-Associated Hypertension in Diabetes Mellitus: The role of O-GlcNAc Modification","volume":"46","author":"Jo","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e13731","DOI":"10.1111\/apha.13731","article-title":"Endothelial Mineralocorticoid Receptor Ablation Confers Protection Towards Endothelial Dysfunction in Experimental Diabetes in Mice","volume":"234","author":"Lyngso","year":"2022","journal-title":"Acta Physiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD (SPin-D): A Randomized, Placebo-controlled, Multiple Dosage Trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized Controlled Trial of the Effect of Spironolactone on Left Ventricular Mass in Hemodialysis Patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","article-title":"Extracellular Cardiac Matrix Biomarkers in Patients with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of Aldosterone to Cardiovascular and Renal Inflammation and Fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2215\/CJN.15841020","article-title":"Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis","volume":"16","author":"Chen","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone Prevents Chronic Kidney Disease Caused by Ischemic Acute Kidney Injury","volume":"83","author":"Reyna","year":"2013","journal-title":"Kidney Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1681\/ASN.2016040477","article-title":"Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1","volume":"28","author":"Lechner","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00166.2005","article-title":"Renocortical mRNA Expression of Vasoactive Factors During Spironolactone Protective Effect in Chronic Cyclosporine Nephrotoxicity","volume":"289","author":"Derive","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.2015.312","article-title":"Deletion of Mineralocorticoid Receptors in Smooth Muscle Cells Blunts Renal Vascular Resistance Following Acute Cyclosporine Administration","volume":"89","author":"Amador","year":"2016","journal-title":"Kidney Int."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic Benefit of Spironolactone in Experimental Chronic Cyclosporine A Nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","article-title":"Prevention of Cardiovascular Disease in Adult Recipients of Kidney Transplants","volume":"378","author":"Jardine","year":"2011","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.transproceed.2010.08.024","article-title":"Addition of Spironolactone to Dual Blockade of Renin Angiotensin System Dramatically Reduces Severe Proteinuria in Renal Transplant Patients: An Uncontrolled Pilot Study at 6 Months","volume":"42","author":"Andres","year":"2010","journal-title":"Transpl. Proc."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000350539","article-title":"Mineralocorticoid Receptor Blockade Reduced Oxidative Stress in Renal Transplant Recipients: A Double-Blind, Randomized Pilot Study","volume":"37","author":"Alberu","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.05300516","article-title":"Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy","volume":"12","author":"Medeiros","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.0000000000000439","article-title":"Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial): A Randomized Placebo-Controlled Clinical Trial","volume":"19","author":"Mortensen","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/1\/53\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:51Z","timestamp":1760115351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/1\/53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["biomedicines13010053"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13010053","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}